OncoZenge

Bolag

OncoZenge

OncoZenge är ett svenskt läkemedelsbolag som utvecklar behandlingar för smärtlindring hos patienter som lider av oral smärta orsakad av strålbehandling och kemoterapi mot cancer. Bolagets produktkandidat är efter genomförda fas 2-studier under vidare utveckling till grund för ansökan om regulatoriska marknadsgodkännanden och kommersialisering. OncoZenge har sitt huvudkontor i Bromma.

Senaste publicering

I databasen

34 publicerade PM

Webbplats

Besök bolagets sida

Senaste nyheter och pressmeddelanden

12 visade
ONCOZ

OncoZenge resolves on a rights issue of approximately SEK 33.3 million and publishes preliminary financial information for the second quarter of 2026

OncoZenge AB (publ) (the “Company” or “OncoZenge”) announces today that the Board of Directors has resolved, based on the authorization granted by the annual general meeting held on May 27, 2026, to carry out a share issue of up to approximately SEK 33.3 million with preferential rights for OncoZenge’s shareholders (the “Rights Issue”). Members of the Board of Directors, senior management and certain larger shareholders have entered into subscription commitments amounting to approximately SEK 5.5 million, corresponding to approximately 16.4 percent of the Rights Issue. In addition, the Company has received guarantee commitments from Vator Securities AB totaling approximately SEK 21.2 million, corresponding to approximately 63.6 percent of the Rights Issue. The Rights Issue is thus covered to approximately 80 percent by subscription and guarantee commitments. The Rights Issue is intended to finance the execution of the Company's Phase III study with BupiZengeTM, as well as related preparatory and operational activities. The Company also publishes preliminary financial information for the second quarter of 2026. For the second quarter of 2026, OncoZenge’s net sales amounted to SEK 5.8 million. The operating loss amounted to SEK 5.4 million (2.6), while the loss after tax amounted to SEK 5.7 million (2.6). Cash flow for the period amounted to SEK -0.2 million (0.3) and earnings per share before and after dilution amounted to SEK -0.40 (-0.22).

ONCOZ

OncoZenge completes partial registration of shares in directed share issue

OncoZenge AB (publ) (“OncoZenge” or the “Company”) announced on 10 July 2026 that the Company had received a partial payment of SEK 5.0 million of the subscription proceeds in the directed share issue of approximately SEK 15.1 million to Sichuan Yangtian Bio-Pharmaceutical Co., Ltd (the “Investor”), resolved by the Board of Directors and announced on 5 June 2026 (the “Directed Share Issue”). The partial payment had a subscription price of SEK 6.47 per share enabling the registration of 772,797 shares in the Directed Share Issue, which have now been registered with the Swedish Companies Registration Office.

ONCOZ

OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds

The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or “the Company”) has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1 million in the directed share issue to Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”), which was resolved by the Board of Directors of the Company and communicated on 5 June 2026 (the “Directed Share Issue”).

ONCOZ

OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds

The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or “the Company”) has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1 million in the directed share issue to Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”), which was resolved by the Board of Directors of the Company and communicated on 5 June 2026 (the “Directed Share Issue”).

ONCOZ

OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds

The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or “the Company”) has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1 million in the directed share issue to Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”), which was resolved by the Board of Directors of the Company and communicated on 5 June 2026 (the “Directed Share Issue”).

ONCOZ

OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds

The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or “the Company”) has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1 million in the directed share issue to Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”), which was resolved by the Board of Directors of the Company and communicated on 5 June 2026 (the “Directed Share Issue”).

ONCOZ

OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds

The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or “the Company”) has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1 million in the directed share issue to Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”), which was resolved by the Board of Directors of the Company and communicated on 5 June 2026 (the “Directed Share Issue”).

ONCOZ

OncoZenge has received partial payment of SEK 5.0 million for subscription proceeds in directed share issue and extends payment deadline

The Board of Directors of OncoZenge AB (publ) ("OncoZenge" or the "Company") informs that it has received a partial payment of SEK 5.0 million of the subscription proceeds in the directed share issue of approximately SEK 15.1 million to Sichuan Yangtian Bio-Pharmaceutical Co., Ltd (the "Investor" or “Yangtian Pharma”), resolved by the Board and communicated on 5 June 2026 (the "Directed Share Issue"). Approximately SEK 10.1 million remains outstanding, and the Board has resolved to extend the payment deadline for this remaining amount to 17 July 2026.

ONCOZ

OncoZenge Extends the Payment Deadline for Subscription Proceeds

The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or “the Company”) has resolved to extend the payment deadline for payment of the subscription proceeds of approximately SEK 15.1 million in the directed share issue to Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”), which was resolved by the Board of Directors of the Company and communicated on 5 June 2026 (the “Directed Share Issue”).

ONCOZ

OncoZenge Extends the Payment Deadline for Subscription Proceeds

The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or “the Company”) has resolved to extend the payment deadline for payment of the subscription proceeds of approximately SEK 15.1 million in the directed share issue to Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”), which was resolved by the Board of Directors of the Company and communicated on 5 June 2026 (the “Directed Share Issue”).

ONCOZ

OncoZenge resolves on a directed share issue to Sichuan Yangtian Bio-Pharmaceutical pursuant to existing investment agreement

The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or the “Company”) has, based on the authorisation granted by the Annual General Meeting on 27 May 2026, resolved on a directed share issue of 2,334,823 shares to the strategic investor Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”) at a subscription price of SEK 6.47 per share (the “Directed Share Issue”). The Directed Share Issue has been resolved upon after the Company received approval of its Phase III Clinical Trial Application (CTA) for BupiZengeTM in Europe. All 2,334,823 shares have been formally subscribed for by the Investor and allotted by the Board of Directors, which means that the Company will receive approximately SEK 15.1 million before deduction of limited administrative transaction costs. The Directed Share Issue constitutes the fourth and final tranche under the SEK 30.2 million investment undertaking (the “Investment”), pursuant to the investment agreement entered into by the Company and the Investor on 27 January 2025 and previously communicated (the “Investment Agreement”).

OncoZenge aktie: nyheter, pressmeddelanden och analys | Tickr